Tuesday, November 24, 2009, 4:28AM AEST - The Australian Stockmarket opens in 5 hours and 32 minutes.
To create a watchlist or portfolio of shares, Register

Aastrom Biosciences, Inc. (ASTM)

4:13AM AEST: 0.3007 USD  Down 0.0093 (3.00%)  
 MORE ON ASTM 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Aastrom Biosciences, Inc. (NCM:ASTM) Delayed quote dataEdit
Last Trade:0.3007 USD
Trade Time: 4:13AM AEST
Change:Down 0.0093 (3.00%)
Prev Close:0.31
Open:0.3009
Bid:0.3007 x 19000
Ask:0.3017 x 800
1y Target Est:0.50
Day's Range:0.295 - 0.31
52wk Range:0.29 - 0.78
Volume:838,907
Avg Vol (3m):1,631,120
Market Cap:52.31M
P/E (ttm):N/A
EPS (ttm):-0.105
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ASTM to Portfolio   Download Data

 HEADLINES 
Updates and Results From Aastrom's Vascular Program Presented at an American Heart Association Satellite Symposium
GlobeNewswire (Mon, Nov 16)
Interim Results From Aastrom's IMPACT-DCM Cardiac Trial Presented at The American Heart Association Meeting
GlobeNewswire (Mon, Nov 16)
AASTROM BIOSCIENCES INC Financials
EDGAR Online Financials (Sat, Nov 14)
Trading Outlook for Hard To Treat Diseases Inc. Issued by InvestorSoup.com
GlobeNewswire (Fri, Nov 13)
Can Stem Cells Put an End To Paralysis?
Indie Research (Thu, Nov 12)
Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure
GlobeNewswire (Wed, Nov 11)
Morningstar Strategist Says Healthcare Bill Will Be Law By End Of Year: Is Your Portfolio Ready?
Wall Street Transcript (Tue, Nov 10)
AASTROM BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Sat, Nov 7)
Aastrom Biosciences Reports First Quarter Fiscal Year 2010 Financial Results
GlobeNewswire (Sat, Nov 7)
Stem Cell Traders Flock to Geron
Indie Research (Sat, Oct 31)
More Headlines for ASTM...

 ANALYST 
EPS Est (next year) (Jun-10) :N/A
EPS Est (in 2 years) (Jun-11) :N/A
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Aastrom Biosciences, Inc. engages in developing autologous cell products for the repair or regeneration of human tissue. Its proprietary tissue repair cell (TRC) technology involves the use of a patient's own cells to manufacture products to ...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices